R01 CA128837/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2008	1
2009	2
2010	5
2011	3
2012	4
2013	3
2014	3
2015	1
2016	2
2024	0

1

Endothelial cells in the eyes of an immunologist.

Young MR. Young MR. Cancer Immunol Immunother. 2012 Oct;61(10):1609-16. doi: 10.1007/s00262-012-1335-0. Epub 2012 Aug 18. Cancer Immunol Immunother. 2012. PMID: 22903347 Free PMC article. Review.

2

Immunotherapy for head and neck cancer: advances and deficiencies.

De Costa AM, Young MR. De Costa AM, et al. Anticancer Drugs. 2011 Aug;22(7):674-81. doi: 10.1097/CAD.0b013e328340fd18. Anticancer Drugs. 2011. PMID: 21037467 Free PMC article. Review.

3

Adipocytes as immune regulatory cells.

Vielma SA, Klein RL, Levingston CA, Young MR. Vielma SA, et al. Int Immunopharmacol. 2013 Jun;16(2):224-31. doi: 10.1016/j.intimp.2013.04.002. Epub 2013 Apr 13. Int Immunopharmacol. 2013. PMID: 23587489 Free PMC article.

4

Premalignant lesions skew spleen cell responses to immune modulation by adipocytes.

Vielma SA, Klein RL, Levingston CA, Young MR. Vielma SA, et al. Anticancer Res. 2013 May;33(5):1809-18. Anticancer Res. 2013. PMID: 23645725 Free PMC article.

5

Treatment to sustain a Th17-type phenotype to prevent skewing toward Treg and to limit premalignant lesion progression to cancer.

Young MR, Levingston CA, Johnson SD. Young MR, et al. Int J Cancer. 2016 May 15;138(10):2487-98. doi: 10.1002/ijc.29989. Epub 2016 Jan 28. Int J Cancer. 2016. PMID: 26756968 Free PMC article.

6

Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma.

Walsh JE, Clark AM, Day TA, Gillespie MB, Young MR. Walsh JE, et al. Hum Immunol. 2010 Jul;71(7):659-65. doi: 10.1016/j.humimm.2010.04.008. Epub 2010 May 16. Hum Immunol. 2010. PMID: 20438786 Free PMC article. Clinical Trial.

7

NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment.

Mailloux AW, Young MR. Mailloux AW, et al. J Immunol. 2009 Mar 1;182(5):2753-65. doi: 10.4049/jimmunol.0801124. J Immunol. 2009. PMID: 19234170 Free PMC article.

8

Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells.

Johnson SD, Levingston C, Young MR. Johnson SD, et al. Anticancer Res. 2016 Jul;36(7):3261-70. Anticancer Res. 2016. PMID: 27354582 Free PMC article.

9

Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck.

De Costa AM, Schuyler CA, Walker DD, Young MR. De Costa AM, et al. Cancer Immunol Immunother. 2012 Jun;61(6):927-39. doi: 10.1007/s00262-011-1154-8. Epub 2011 Nov 25. Cancer Immunol Immunother. 2012. PMID: 22116344 Free PMC article.

10

Cytokine and Adipokine Levels in Patients with Premalignant Oral Lesions or in Patients with Oral Cancer Who Did or Did Not Receive 1α,25-Dihydroxyvitamin D3 Treatment upon Cancer Diagnosis.

Young MR, Levingston C, Johnson SD. Young MR, et al. Cancers (Basel). 2015 Jun 25;7(3):1109-24. doi: 10.3390/cancers7030827. Cancers (Basel). 2015. PMID: 26120967 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

23 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year